The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Statins for Improving Renal Outcomes: A Meta-Analysis
Open accessAbstract
Statins frequently are used to prevent cardiovascular events. Several recent studies suggest that statins also may have renal benefits, although this is controversial. This systematic review and meta-analysis were performed to assess the effect of statins on change in kidney function and urinary protein excretion. Medline, EMBASE, the Cochrane Central Register of Controlled Trials, conference proceedings, and the authors' personal files were searched. Published or unpublished randomized, controlled trials or crossover trials of statins that reported assessment of kidney function or proteinuria were included, and studies of individuals with ESRD were excluded. Data were extracted for study design, subject characteristics, type of statin and dose, baseline/change in cholesterol levels, and outcomes (change in measured or estimated GFR [eGFR] and/or urinary protein excretion). Weighted mean differences were calculated for the change in GFR between statin and control groups using a random-effects model. A random-effects model also was used to calculate the standardized mean difference for the change in urinary protein excretion between groups. Twenty-seven eligible studies with 39,704 participants (21 with data for eGFR and 20 for proteinuria or albuminuria) were identified. Overall, the change in the weighted mean differences for eGFR was statistically significant (1.22 ml/min per yr slower in statin recipients; 95% confidence interval [CI] 0.44 to 2.00). In subgroup analysis, the benefit of statin therapy was statistically significant in studies of participants with cardiovascular disease (0.93 ml/min per yr slower than control subjects; 95% CI 0.10 to 1.76) but was NS for studies of participants with diabetic or hypertensive kidney disease or glomerulonephritis. The standardized mean difference for the reduction in albuminuria or proteinuria as a result of statin therapy was statistically significant (0.58 units of SD greater in statin recipients; 95% CI 0.17 to 0.98). Statin therapy seems to reduce proteinuria modestly and results in a small reduction in the rate of kidney function loss, especially in populations with cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
Clinical epidemiology of cardiovascular disease in chronic renal disease
Foley, R., Parfrey, P., & Sarnak, M. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9820470 · Cited by 3,958
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
Charbonneau, D. H. (2005) · Europe PMC (PubMed Central) · Cited by 2,041
Variance imputation for overviews of clinical trials with continuous response
Follmann, D., Elliott, P., Suh, I., & Cutler, J. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90054-q · Cited by 1,385
Mann, J. F. E., Gerstein, H. C., Pogue, J., Bosch, J., Yusuf, S., & for the HOPE Investigators (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00007 · Cited by 1,372
Jafar, T. H., Schmid, C. H., Landa, M., Giatras, I., Toto, R., Remuzzi, G., Maschio, G., Brenner, B. M., Kamper, A., Zucchelli, P., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-2-200107170-00007 · Cited by 1,092
Simvastatin, an HMG–Coenzyme A Reductase Inhibitor, Improves Endothelial Function Within 1 Month
O'Driscoll, G., Green, D., & Taylor, R. R. (1997) · Circulation · doi:10.1161/01.cir.95.5.1126 · Cited by 952
Effect of lipid reduction on the progression of renal disease: A meta-analysis
Fried, L. F., Orchard, T. J., & Kasiske, B. L. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00487.x · Cited by 672
Self-citationSerum creatinine levels in the US population: Third National Health and Nutrition Examination Survey
Jones, C., McQuillan, G., Kusek, J., Eberhardt, M., Herman, W., Coresh, J., Salive, M., Jones, C., & Agodoa, L. (1998) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(98)70074-5 · Cited by 572
Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria
Asselbergs, F. W., Diercks, G. F. H., Hillege, H. L., van Boven, A. J., Janssen, W. M. T., Voors, A. A., de Zeeuw, D., de Jong, P. E., van Veldhuisen, D. J., & van Gilst, W. H. (2004) · Circulation · doi:10.1161/01.cir.0000146378.65439.7a · Cited by 523
Cholesterol and the risk of renal dysfunction in apparently healthy men
Schaeffner, E. S., Kurth, T., Curhan, G. C., Glynn, R. J., Rexrode, K. M., Baigent, C., Buring, J. E., & Gaziano, J. M. (2003) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1482084 · Cited by 442
Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats
Kasiske, B. L., O'donnell, M. P., Cleary, M. P., & Keane, W. F. (1988) · Kidney International · doi:10.1038/ki.1988.51 · Cited by 409
LEVEY, A. S., GREENE, T., BECK, G. J., CAGGIULA, A. W., KUSEK, J. W., HUNSICKER, L. G., & KLAHR, S. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v10112426 · Cited by 399
Athyros, V. G., Mikhailidis, D. P., Papageorgiou, A. A., Symeonidis, A. N., Pehlivanidis, A. N., Bouloukos, V. I., & Elisaf, M. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.012989 · Cited by 353
Bianchi, S., Bigazzi, R., Caiazza, A., & Campese, V. M. (2003) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2003.50140 · Cited by 332
Effective care of the newborn infant
Sinclair, J. C., Bracken, M. B., & Silverman, W. A. (1992) · Oxford University Press eBooks · Cited by 328
Study of Heart and Renal Protection (SHARP)
Baigent, C., & Landry, M. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s84.4.x · Cited by 320
Smoking as a risk factor for end-stage renal failure in men with primary renal disease
Orth, S. R., Stöckmann, A., Conradt, C., Ritz, E., Ferro, M., Kreusser, W., Piccoli, G., Rambausek, M., Roccatello, D., Schäfer, K., et al. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00067.x · Cited by 314
Kasiske, B. L., O'Donnell, M. P., Garvis, W. J., & Keane, W. F. (1988) · Circulation Research · doi:10.1161/01.res.62.2.367 · Cited by 291
Renal injury of diet-induced hypercholesterolemia in rats
Kasiske, B. L., O'Donnell, M. P., Schmitz, P. G., Kim, Y., Keane, W. F., Phillips, W. T. T. A. O. F., Daniels, F., & Holden, G. (1990) · Kidney International · doi:10.1038/ki.1990.62 · Cited by 268
Samuelsson, O., Mulec, H., Knight-Gibson, C., Attman, P., Kron, B., Larrson, R., Weiss, L., Wedel, H., & Alaupovic, P. (1997) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/12.9.1908 · Cited by 234
Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease
Tonelli, M., Isles, C., Craven, T., Tonkin, A., Pfeffer, M. A., Shepherd, J., Sacks, F. M., Furberg, C., Cobbe, S. M., Simes, J., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.517565 · Cited by 197
Self-citationCholesterol-lowering therapy may retard the progression of diabetic nephropathy
Lam, K. S. L., Cheng, I. K. P., Janus, E. D., & Pang, R. W. C. (1995) · Diabetologia · doi:10.1007/bf00400731 · Cited by 194
Tonolo, G., Ciccarese, M., Brizzi, P., Puddu, L., Secchi, G., Calvia, P., Atzeni, M. M., Melis, M. G., & Maioli, M. (1997) · Diabetes Care · doi:10.2337/diacare.20.12.1891 · Cited by 168
How To Fully Protect the Kidney in a Severe Model of Progressive Nephropathy: A Multidrug Approach
Zoja, C., Corna, D., Camozzi, D., Cattaneo, D., Rottoli, D., Batani, C., Zanchi, C., Abbate, M., & Remuzzi, G. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000034912.55186.ec · Cited by 167
Pooling Research Results: Benefits and Limitations of Meta-Analysis
Ioannidis, J. P. A., & Lau, J. (1999) · The Joint Commission Journal on Quality Improvement · doi:10.1016/s1070-3241(16)30460-6 · Cited by 158
Effect of combining ACE inhibitor and statin in severe experimental nephropathy
Zoja, C., Corna, D., Rottoli, D., Cattaneo, D., Zanchi, C., Tomasoni, S., Abbate, M., & Remuzzi, G. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00332.x · Cited by 116
Effect of Pravastatin on Proteinuria in Patients With Well-Controlled Hypertension
Lee, T., Su, S.-F., & Tsai, C. (2002) · Hypertension · doi:10.1161/01.hyp.0000022805.11288.7f · Cited by 113
Nielsen, S., Schmitz, O., Møller, N., Pøksen, N., Klausen, I. C., Alberti, K. G. M. M., & Mogensen, C. E. (1993) · Diabetologia · doi:10.1007/bf02374502 · Cited by 100
Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy
Hommel, E. E., Andersen, P. H., Gall, M. ‐., Nielsen, F. S., Jensen, B., Rossing, P. R., Dyerberg, J., & Parving, H. ‐. (1992) · Diabetologia · doi:10.1007/bf02342442 · Cited by 97
Thomas, M. E., Harris, K. P. G., Ramaswamy, C., Hattersley, J., Wheeler, D. C., Varghese, Z., Williams, J. D., Walls, J., & Moorhead, J. F. (1993) · Kidney International · doi:10.1038/ki.1993.358 · Cited by 95
Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease
van Dijk, M. A., Kamper, A. M., van Veen, S., Souverijn, J. H. M., & Blauw, G. J. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.11.2152 · Cited by 94
Lipids and progressive kidney disease.
Moorhead, J. F. (1991) · PubMed · Cited by 91
Lovastatin Retards the Progression of Established Glomerular Disease in Obese Zucker Rats
O’Donnell, M. P., Kasiske, B. L., Kim, Y., Schmitz, P. G., & Keane, W. F. (1993) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)70172-5 · Cited by 91
Nakamura, T., Ushiyama, C., Hirokawa, K., Osada, S., Shimada, N., & Koide, H. (2001) · American Journal of Nephrology · doi:10.1159/000046648 · Cited by 86
Apolipoprotein B-containing lipoproteins in renal failure: The relation to mode of dialysis
Attman, P., Samuelsson, O. G., Moberly, J. B., Johansson, A., Ljungman, S., Weiss, L. G., Knight‐Gibson, C., & Alaupovic, P. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00375.x · Cited by 85
Lipid modulation in insulin-dependent diabetes mellitus
Fried, L. F., Forrest, K. Y. Z., Ellis, D., Chang, Y., Silvers, N., & Orchard, T. J. (2001) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(01)00140-4 · Cited by 84
Self-citationEffect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy
Buemi, M. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.105330 · Cited by 78
Lovastatin inhibits lipopolysaccharide-induced NF-kB activation in human mesangial cells
Guijarro, C., Kim, Y., Schoonover, C. M., Massy, Z. A., O’Donnell, M. P., Kasiske, B. L., Keane, W. F., & Kashtan, C. E. (1996) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/11.6.990 · Cited by 65
THE PERCENTAGE LIMITS FOR THE DISTRIBUTION OF RANGE IN SAMPLES FROM A NORMAL POPULATION. (n ≤ 100.)
Pearson, E. S. (1932) · Biometrika · doi:10.1093/biomet/24.3-4.404 · Cited by 63
Simvastatin in nephrotic syndrome
Olbricht, C. J., for the Simvastatin In Nephrotic Syndrome Study Group, Wanner, C., Thiery, J., & Basten, A. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.07128.x · Cited by 55
Rayner, B. L., Byrne, M., & van Zyl-Smit, R. N. (1996) · PubMed · Cited by 53
Zhang, A., Vertommen, J., Gaal, L. V., & Leeuw, I. D. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01138-2 · Cited by 45
Lee, T., Lin, M., Tsai, C., & Chang, N. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00457.x · Cited by 33
Imai, Y., Suzuki, H., Saito, T., Tsuji, I., Abe, K., & Saruta, T. (1999) · Clinical and Experimental Hypertension · doi:10.3109/10641969909070853 · Cited by 29
Fluvastatin for dyslipoproteinemia,with or without concomitant chronic renal insufficiency
Lintott, C. J., Scott, R. S., Bremer, J. M., & Shand, B. I. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(05)80027-x · Cited by 28
Safety and Efficacy of Fluvastatin in Hyperlipidemic Patients With Chronic Renal Disease
Yasuda, G., Kuji, T., Hasegawa, K., Ogawa, N., Shimura, G., Ando, D., & Umemura, S. (2004) · Renal Failure · doi:10.1081/jdi-120039826 · Cited by 24
Scanferla, F., Toffoletto, P., Roncali, D., & Bazzato, G. (1991) · American Journal of Hypertension · doi:10.1093/ajh/4.10.868 · Cited by 17
[Effect of pravastatin on hypercholesterolemia associated with proteinuria].
Arcas, J. L. A., Sánchez, R., Guijarro, C., Araque, A., Pulido, F., Praga, M., & Damiano, A. (1994) · PubMed · Cited by 10
Cited by
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Authors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Graham (2007) · doi:10.1097/01.hjr.0000277983.23934.c9 · Cited by 1,647
Metadata
- Authors
- Sandhu, S., Wiebe, N., Fried, L. F., & Tonelli, M.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2006-07
- Volume
- 17
- Issue
- 7
- Pages
- 2006-2016
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2042318705
- Cited by
- 478
- References
- 61
- FWCI
- 28.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.